In vitro susceptibility of clinically important zygomycetes to combinations of amphotericin B and suramin

Journal de Mycologie Medicale

Volumn 19, Issue 4, 2009, Pages 241-247

  Galgoczy L ^a   Ordogh L ^a   Viragh M ^a   Papp, T ^a   Vagvolgyi Cs ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Amphotericin B; Drug combinations; MIC; Suramin; Zygomycetes

Indexed keywords

AMPHOTERICIN B; SURAMIN;

ABSIDIA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; MICROMUCOR; MORTIERELLA; MUCOR; MYCOCLADUS; NONHUMAN; RHIZOMUCOR; RHIZOPUS; SAKSENAEA; SYNCEPHALASTRUM; ZYGOMYCETES;

ABSIDIA; FUNGI; MICROMUCOR; MORTIERELLA; MUCOR; RHIZOMUCOR; RHIZOPUS; SAKSENAEA; SYNCEPHALASTRUM; ZYGOMYCETES;

EID: 70849137348     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2009.09.004     Document Type: Article

References (33)

1. Almyroudis N.G., Sutton D.A., Fothergill A.W., Rinaldi M.G., and Kusne S. In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 51 (2007) 2587-2590
2. Bapiro T.E., Egnell A.-C., Hasler J.A., and Masimirembwa C.M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S. Drug Metab Dispos 29 (2001) 30-35
3. Chayakulkeeree M., Ghannoum M.A., and Perfect J.R. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 25 (2006) 215-229
4. Dannaoui E., Afeltra J., Meis J.F.G.M., Verweij P.E., and The Eurofung Network. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 46 (2002) 2708-2711
5. Eliopoulos G.M., and Moellering R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in Laboratory Medicine. 4th edn. (1996), Williams and Wilkins, Baltimore 330-396
6. Eucker J., Sezer O., Graf B., and Possinger K. Mucormycoses. Mycoses 44 (2001) 253-260
7. Freifeld A.G., and Iwen P.C. Zygomycosis. Semin Respir Crit Care Med 25 (2004) 221-232
8. Galgóczy L., Papp T., and Vágvölgyi Cs. In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. Mycoses 52 (2009) 447-453
9. Gallagher C.G., Ashley E.S.D., Drew R.H., and Perfect J.R. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 4 (2003) 147-164
10. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans. J Infect Dis 182 (2000) 274-282
11. Gschwendt M., Kittstein W., and Johannes F.-J. Differential effects of suramin on protein kinase C isoenzymes. A novel tool for discriminating protein kinase C activities. FEBS Lett 421 (1998) 165-168
12. Herrmann M., Spröte P., and Brakhage A.A. Protein kinase C (PkcA) of Aspergillus nidulans is involved in penicillin production. Appl Environ Microbiol 72 (2006) 2957-2970
13. Hussain M., Fisher E.I., Petrylak D.P., O'Connor J., Wood D.P., Small E.J., et al. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate Cancer: a southwest oncology group study. J Clin Oncol 18 (2000) 1043-1049
14. Larabi M., Pages N., Pons F., Appel M., Gulik A., Schlatter J., et al. Study of the toxicity of a new lipid complex formulation of amphotericin B. J Antimicrob Chemother 53 (2004) 81-88
15. Lawrence J.J.B., Conover C.A., Haddad T.C., Ingle J.N., Reid J.M., Ames M.M., et al. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res 3 (1997) 1713-1720
16. Meletiadis J., te Dorsthorst D.T.A., and Verweij P.E. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int J Antimicrob Agents 28 (2006) 439-449
17. Minassian B., Huczko E., Washo T., Bonner T., and Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes. Scedosporium and Fusarium isolates. Clin Microbiol Infect 9 (2003) 1250-1252
18. Moreno A.B., del Pozo A.M., Borja M., and San Segudo B. Activity of the antifungal protein from Aspergillus giganteus against Botrytis cinerea. Phytopathology 93 (2003) 1344-1353
19. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. Wayne, Pennsylvania, USA: NCCLS; 2002.
20. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16 (2003) 607-612
21. Olgemöller B., Deufel T., Schleicher E., and Gerbitz K.-D. Rapid determination of serum suramin levels using isocratic HPLC separation. Fresenius J Anal Chem 324 (1986) 356
22. Perkhofer S., Locher M., Cuenca-Estrella M., Rüchel R., Würzner R., Dierich M.P., et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother 52 (2008) 2636-2638
23. Prabhu R.M., and Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 10 (2004) 31-47
24. Ribes J.A., Vanhover-Sams C.L., and Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 13 (2000) 236-301
25. Rodriguez-Tudela JL, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, et al. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST Discussion Document, European Committee on Antimicrobial Susceptibility Testing. Switzerland: European Society of Clinical Microbiology and Infectious Disease; 2007.
26. Rogers T.R. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61 (2008) 35-39
27. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
28. Takó M., and Csernetics A. Genotypic analysis of variability in zygomycetes. Acta Biol Hung 56 (2005) 345-357
29. Vazquez J.A. Combination antifungal therapy: the new frontier. Future Microbiol 2 (2007) 115-139
30. Vicente M.F., Basilio A., Cabello A., and Pelaez F. Microbial natural products as a source of antifungals. Clin Microbiol Infect 9 (2003) 15-32
31. Villalona-Calero M.A., Wientjes M.G., Otterson G.A., Kanter S., Young D., Murgo A.J., et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 9 (2003) 3303-3311
32. Walsh T.J., Groll A., Hiemenz J., Fleming R., Roilides E., and Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10 (2004) 48-66
33. Westermann A.M., Dubbelman R., Moolenaar W.H., Beijnen J., and Rodenhuis S. Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann Oncol 8 (1997) 801-802